Table 1.
Baseline characteristics of included patients, comparing patients with identified BE/IM to those without BE/IM in the Mayo Clinic (A) and OCCAMS cohort (B)
| (A) Mayo | (B) OCCAMS | |||||||
|---|---|---|---|---|---|---|---|---|
| BE/IM, n=204 | Non-BE/IM, n=207 | P value | Total, n=411 | BE/IM n=634 | Non-BE/IM, n=783 | P value | Total n=1417 | |
| Age at diagnosis, mean years (SD) | 65 (10.4) | 63 (11) | 0.02 | 64 (10.7) | 67 (9) | 66 (9.8) | 0.06 | |
| Male, n (%) | 172 (84) | 178 (86) | 0.6 | 350 (85.2) | 539 (85) | 640 (81.7) | 0.1 | 1179 (83.2) |
| BMI, mean (SD, IQR) | 29.4 (5, 26-32) | 29 (5.4, 25-33) | 0.6 | 29 (5.3, 25-32) | 28 (5, 25-31) | 27 (4.8, 24-29) | < 0.001 | |
| History or current Smoking, n (%) | 128 (63) | 128 (62) | 0.2 | 256 (62.3) | 362 (57.1) | 456 (58.2) | 0.07 | 818 (57.7) |
| Family history of EAC, n (%) | 9 (4.4) | 11 (5.3) | 0.6 | 20 (5) | 39 (6.2) | 39 (5) | 0.662 | 78 (5.5) |
| TNM Stage, n (%) | <0.001 | < 0.001 | ||||||
| I | 62 (30.4) | 10 (4.8) | 72 (17.5) | 53 (8.4) | 17 (2.2) | 70 (4.9) | ||
| II | 55 (27) | 37 (17.9) | 92 (22.4) | 323 (50.9) | 339 (43.3) | 662 (46.7) | ||
| III | 61 (29.9) | 93 (44.9) | 154 (37.5) | 195 (30.8) | 285 (36.4) | 480 (33.9) | ||
| IV | 26 (12.7) | 67 (32.4) | 93 (22.6) | 8 (1.3) | 46 (5.9) | 54 (3.8) | ||
| Missing | 0 | 0 | 0 | 55 (8.7) | 96 (12.3) | 151 (10.7) | ||
| T stage, n (%) | <0.001 | <0.001 | ||||||
| T0 | 0 | 0 | 0 | 10 (1.6) | 3 (0.4) | 13 (0.9) | ||
| T1 | 66 (32.4) | 11 (5.3) | 77 (18.7) | 70 (11) | 21 (2.7) | 91 (6.4) | ||
| T2 | 41 (20.1) | 23 (11.1) | 64 (15.6) | 86 (13.6) | 60 (7.7) | 146 (10.3) | ||
| T3 | 46 (37.3) | 107 (51.7) | 183 (44.5) | 380 (59.9) | 511 (65.3) | 891 (62.9) | ||
| T4 | 1 (0.5) | 4 (1.9) | 5 (1.2) | 34 (5.4) | 95 (12.1) | 129 (9.1) | ||
| Missing | 20 (9.8) | 62 (30) | 82 (20) | 52 (8.2) | 93 (11.9) | 145 (10.2) | ||
| N stage, n (%) | <0.001 | < 0.001 | ||||||
| N0 | 89 (43.6) | 32 (15.5) | 121 (29.4) | 155 (24.4) | 146 (18.6) | 301 (21.2) | ||
| N1 | 77 (37.8) | 84 (40.6) | 161 (39.2) | 205 (32.3) | 230 (29.4) | 435 (30.7) | ||
| N2 | 12 (5.9) | 20 (9.7) | 32 (7.8) | 139 (21.9) | 190 (24.3) | 329 (23.2) | ||
| N3 | 5 (2.5) | 8 (3.9) | 13 (3.2) | 76 (12) | 139 (17.8) | 215 (15.2) | ||
| Missing | 21 (10.3) | 63 (30.4) | 84 (20.4) | 53 (8.4) | 78 (10) | 131 (9.2) | ||
| Location (Siewert class), n (%) | 0.8 | < 0.001 | ||||||
| 1 (Distal 1-5cm above EGJ) | 109 (53.4) | 117 (56.5) | 226 (55) | 222 (35) | 173 (22.1) | 395 (27.9) | ||
| 2 (1cm above- 2cm below EGJ) | 86 (42.2) | 80 (38.6) | 166 (40.4) | 213 (33.6) | 288 (36.8) | 501 (35.4) | ||
| 3 (2-5 cm below EGJ) | -- | -- | -- | 50 (7.9) | 125 (16) | 175 (12.4) | ||
| Missing | 4 (2) | 6 (2.9) | 10 (2.4) | 149 (23.5) | 197 (25.2) | 346 (24.4) | ||
| Tubular esophagus above 5 cm | 5 (2.4) | 4 (2) | 9 (2.2) | -- | -- | -- | ||
| Treatment, n (%) | <0.001 | < 0.001 | ||||||
| Endoscopic therapy | 37 (18.1) | 2 (1) | 39 (9.5) | -- | -- | -- | ||
| Esophagectomy alone | 31 (15.2) | 10 (4.8) | 41 (9.9) | 137 (21.6) | 114 (14.6) | 251 (17.7) | ||
| Neoadjuvant chemotherapy & esophagectomy | 93 (45.6) | 91 (44) | 184 (44.8) | 416 (65.6) | 518 (66.2) | 934 (65.9) | ||
| Esophagectomy & adjuvant chemo-radiation | 5 (2.4) | 4 (1.9) | 9 (2.2) | -- | -- | -- | ||
| Chemo and/or radiation therapy alone | 29 (14.2) | 79 (38.2) | 108 (26.3) | 25 (3.9) | 76 (9.7) | 101 (7.1) | ||
| Palliative | 4 (2) | 17 (8.2) | 21 (5.1) | 13 (2.1) | 76 (9.7) | 89 (6.3) | ||
| Missing | 5 (2.4) | 4 (1.9) | 9 (2.2) | -- | -- | -- | ||